GlassScriptPhysician profile
Daniel Carrero
NPI 1366998510
$7,813.09
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.95 · 2021: $353 · 2022: $5,160 · 2023: $2,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,100 · Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,100.00 |
| Food and Beverage | $157.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,984.49 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $191.36 | 2020-2023 | Spravato |
| Lundbeck LLC | $98.86 | 2022-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $98.10 | 2021-2022 | |
| Indivior INC. | $87.20 | 2021-2023 | Perseris |
| Teva Pharmaceuticals USA, INC. | $69.17 | 2021-2023 | Austedo |
| Alkermes, INC. | $67.83 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.67 | 2021-2022 | |
| Corium, LLC | $45.78 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $39.78 | 2022 | |
| Neurocrine Biosciences, INC. | $28.29 | 2022 | |
| Sunovion Pharmaceuticals INC. | $27.48 | 2021 | |
| Allergan, INC. | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Carrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.